Cingulate (NASDAQ:CING) said it has completed a Phase 3 study for its drug candidate CTx-1301 in the treatment of ADHD in adults and has slated the initiation of a pivotal Phase 3 pediatric study to ...
KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results